Brands, Medical Use, Clinical Data
Brands / Synonyms
DACPLAT; Eloxatin; Oxalatoplatin; Oxalatoplatinum; Oxaliplatin [Usan:Inn:Ban]; Oxaliplatino [Spanish]; Oxaliplatinum [Latin]; Oxaloplatine [French]; Oxaloplatino [Spanish]
For the treatment of malignant neoplasm of colon, rectum, and ovary
Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
Mechanism of Action
after activationm it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
Biotrnasformation / Drug Metabolism
ELOXATIN should not be administered to patients with a history of known allergy to ELOXATIN or other platinum
No specific cytochrome P450-based drug interaction studies have been conducted. No pharmacokinetic interaction
between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks.
Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2
ELOXATIN dosed every 3 weeks. Since platinum containing species are eliminated primarily through the kidney,
clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; although, this
has not been specifically studied.